US FDA to Review GSK’s Blenrep Combo for Relapsed/Refractory Multiple Myeloma
GSK plc has disclosed that the United States Food and Drug Administration (FDA) has agreed to review the Biologics License Application (BLA) for Blenrep (belantamab mafodotin) when combined with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]). […]
US FDA to Review GSK’s Blenrep Combo for Relapsed/Refractory Multiple Myeloma Read More »